Previous Study: BCIRG 004
Next Study: BCIRG 006

Studies & Results

BCIRG 005

A multicenter phase III randomized trial comparing docetaxel in combination with doxorubicin and cyclophosphamide (TAC) versus doxorubicin and cyclophosphamide followed by docetaxel (AC-T) as adjuvant treatment of operable breast cancer HER2neu negative patients with positive axillary lymph nodes

View FDA Study

Presentations

ASCO Annual Meeting, 2016

Pan H, Gray R, Davies C, et al.

Long-term recurrence risks after use of endocrine therapy for only 5 years: Relevance of breast tumour characteristics.

San Antonio Breast Cancer Symposium, 2012

Christiansen J, Barakat N, Murphy D, et al

Her2 expression measured by AQUA analysis on BCIRG-005 and BCIRG-006 predicts the benefit of Herceptin therapy.

San Antonio Breast Cancer Symposium, 2008

Eiermann W, Pienkowski T, Crown J, et al

BCIRG 005 main efficacy analysis: a phase III randomized trial comparing docetaxel in combination with doxorubicin and cyclophosphamide (TAC) versus doxorubicin and cyclophosphamide followed by docetaxel (AC→T) in women with Her-2/neu negative axillary lymph node positive early breast cancer.

Publications

Press MF, Sauter G, Buyse M, et al.: HER2 Gene Amplification Testing by Fluorescent In Situ Hybridization (FISH): Comparison of the ASCO-College of American Pathologists Guidelines With FISH Scores Used for Enrollment in Breast Cancer International Research Group Clinical Trials. J Clin Oncol JCO.2016.66.6693, 2016

Mackey J, Penkowski T, Crown J, et al.: Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial Ann Oncol 27:1041-7, 2016

Stern HM, Gardner H, Burzykowski T, et al: PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance. Clin Cancer Res Off J Am Assoc Cancer Res 21:2065–2074, 2015

Perez EA, Press MF, Dueck AC, et al: Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005). Breast Cancer Res Treat 138:99–108, 2013

Dang C: The End of an Era: Shall We Move Forward? J Clin Oncol 29:3849–3851, 2011

Eiermann W, Pienkowski T, Crown J, et al: Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial. J Clin Oncol Off J Am Soc Clin Oncol 29:3877–3884, 2011

Press MF, Sauter G, Buyse M, et al: Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy. J Clin Oncol Off J Am Soc Clin Oncol 29:859–867, 2011

For information on any of TRIO's clinical trials, please contact Valérie Bee, Director Project Management at valerie.bee@trioncology.org